ClinicalTrials.Veeva

Menu

CRP /albumin Ratio and Neutrophil Lymphocyte Ratio in Predicting Activity in IBD Patients

A

Assiut University

Status

Not yet enrolling

Conditions

Inflammatory Bowel Disease (IBD)

Study type

Observational

Funder types

Other

Identifiers

NCT06750315
CRP/ALB and N/L In active IBD

Details and patient eligibility

About

This study aimed to assess the clinical utility of the NLR (neutrophil lymphocyte ratio) and CRP Albumin ratio in predicting activity of IBD Patients in assiut university

Full description

IBD definition term for two conditions (Crohn's disease and ulcerative colitis) is a chronic idiopathic inflammatory disease affecting the large intestine. It is characterized by relapsing mucosal inflammation. The aim of treatment is to induce and maintain disease remission. Assessing disease activity may help in optimizing the management of IBD patients.

The neutrophil-to-lymphocyte ratio (NLR) is a simple index that can be calculated from the results of ordinary blood tests; it is calculated from a blood sample by dividing the absolute neutrophil count by the absolute lymphocyte count . As the NLR can reflect the systemic status of inflammation or immune response.

The underlying mechanism that the NLR was a predictor of clinilcal relapse in UC patients with Mucosal healing remains poorly understood. Neutrophils induce cytotoxicity and inflammation in UC. A high NLR value may be due to high activity in UC and lowered mucosal barrier function, which may lead to the migration of neutrophils through the gut microbiota .

CRP is routinely used as a surrogate measure of intestinal inflammation and as a prognostic measure of nonresponse to medical therapy and colectomy in patients with IBD.

Enrollment

35 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients more than 18 years newly diagnosed as IBD

Exclusion criteria

  • Patients Not DM Not cardiac failure Not Liver failure No malignancy

Trial contacts and locations

2

Loading...

Central trial contact

Amira Mohamed Ali Ahmed

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems